The agreement – which focuses on autoimmune diseases lupus and rheumatoid arthritis (RA) – comes almost two years after EVOQ penned a $240 million deal with Amgen that also focused on using the NanoDisc platform for autoimmune disorder therapies.
For both deals, the total potential value has been given, but there’s no detail on the split between upfront and follow-up payments. They both also include tiered royalties on sales of any products emerging from the partnerships.
